TARGETED THERAPIES
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
What is the way forward for undruggable tumour targets?
2026 ESMO TAT Honorary Awardee, Prof. Timothy A. Yap, sees a bright future ahead for novel synthetic lethal strategies, driven by advances in technology and novel biomarkers
OTHER NEWS
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
LATEST FROM ESMO
How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
OPINIONS
Redesigning oncology clinical trials with agentic AI
Jorge Reis-Filho
From bispecific to multispecific antibodies: a highly promising field
Nina Weisser
The challenge of undifferentiated sarcomas
Pawel Sobczuk
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle
OPINIONS
Redesigning oncology clinical trials with agentic AI
Jorge Reis-Filho
From bispecific to multispecific antibodies: a highly promising field
Nina Weisser
The challenge of undifferentiated sarcomas
Pawel Sobczuk
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle